Canada: Patent

The Supreme Court of Canada has released its highly anticipated decision in Pharmascience Inc. v. Janssen Inc.1, upholding the validity of Janssen’s patent for a long-acting dosing regimen for the treatment...

The Supreme Court of Canada has issued its most significant ruling on medical treatment patents in over fifty years, addressing whether dosing-regimen claims for schizophrenia medication constitute unpatentable methods of medical treatment. The 7-2 decision establishes a new framework for evaluating pharmaceutical patents, focusing on whether implementing the claimed invention requires professional medical skill and judgment. This landmark case provides crucial guidance for life sciences companies seeking p

La Cour suprême du Canada a rendu une décision historique confirmant que les méthodes de traitement médical demeurent non brevetables lorsqu'elles monopolisent la compétence et le jugement professionnels des médecins.

La Cour suprême du Canada a rendu sa décision dans l'affaire Pharmascience Inc. c. Janssen Inc., 2026 CSC 26, concernant la brevetabilité des méthodes de traitement médical. La décision clarifie l'approche permettant de déterminer si une revendication constitue une méthode de traitement médical non brevetable, tout en confirmant la validité du brevet de Janssen sur un schéma posologique de palipéridone pour le traitement de la schizophrénie.

The Supreme Court of Canada has ruled on the patentability of methods of medical treatment in Canada, affirming that such methods remain unpatentable while upholding the validity of Janssen's patent for a paliperidone palmitate dosing regimen. The decision provides crucial guidance on determining whether pharmaceutical claims constitute unpatentable medical treatment methods, focusing on the role of professional medical skill and judgment in practicing the claimed invention.

The Supreme Court of Canada has issued a landmark ruling on whether methods of medical treatment can be patented in Canada, addressing a long-standing prohibition that has shaped the country's intellectual property landscape. The decision examines the boundaries between patentable medical innovations and unpatentable professional medical judgment, with particular focus on dosing regimens and treatment protocols. This ruling provides critical guidance for pharmaceutical companies, patent practitioners, and h

The Canadian Intellectual Property Office has issued a preliminary redetermination following the Federal Court's remand in Dusome v. Canada, applying a revised patentable subject matter framework to a poker game patent application.

Saskatchewan startups often discover too late that unclear intellectual property ownership can derail fundraising and acquisitions. When founders, contractors, or employees contribute to a company's IP without proper documentation...

AccelerateIP offers Canadian startups substantial funding and mentorship to develop intellectual property strategies, with three program streams providing up to $85,000 in combined support for IP development, legal costs...